Placental Growth Factor Diagnostic Testing: An Opportunity to Transform Pregnancy Care for Patients With Suspected Preeclampsia in Canada

J Obstet Gynaecol Can. 2025 Oct;47(10):103076. doi: 10.1016/j.jogc.2025.103076. Epub 2025 Aug 14.

Abstract

Preeclampsia is a leading cause of maternal morbidity and adverse perinatal outcomes in Canada. Growing evidence supports the novel blood-based biomarker placental growth factor (PlGF) as a diagnostic test to accelerate the timely diagnosis of preeclampsia, enhancing care for hypertensive pregnant patients. Despite national endorsement, challenges like regional disparities and test standardization hinder PlGF implementation. The Canadian PlGF Strategy & Research Consortium convened with representation from clinicians, researchers, and patient partners to discuss the current state of PlGF testing. We universally agreed there is an urgent need to implement diagnostic PlGF testing to improve maternal and perinatal outcomes in Canada.

Keywords: maternal health; obstetrics; placental growth factor (PlGF); preeclampsia.

MeSH terms

  • Biomarkers / blood
  • Canada
  • Female
  • Humans
  • Placenta Growth Factor* / blood
  • Pre-Eclampsia* / blood
  • Pre-Eclampsia* / diagnosis
  • Pregnancy

Substances

  • Placenta Growth Factor
  • Biomarkers
  • PGF protein, human